Upload
sayed-nour
View
225
Download
0
Embed Size (px)
Citation preview
7/31/2019 Thrombo Prophylaxis
1/120
THROMBO
PROPHYLAXIS
7/31/2019 Thrombo Prophylaxis
2/120
1. Which of the following statements iscorrect?
a. The annual incidence of venousthromboembolism is 20/100,000
b. The risk of a DVT after a hip replacement isaround 50%
c. 90-day mortality from a treated PE is 10%
d. Factor II is also known as prothrombin
7/31/2019 Thrombo Prophylaxis
3/120
2. Are proteins C and S
pro-coagulant oranticoagulant?
7/31/2019 Thrombo Prophylaxis
4/120
3. Which of the following aremajor risks factors for venous
thromboembolism? a. Malignancy
b. Varicose veins
c. Post-operative intensive care
d. Thoracic surgery
7/31/2019 Thrombo Prophylaxis
5/120
4. Which of the following statements iscorrect:
a. In cases of HIT, it is recommended totransfuse platelets once below 20,000 !109/L.
b. Patients with HIT should beanticoagulated.
c. HIT should only be treated if the patienttests positive for HIT antibodies.
d. Patients with HIT are allergic to heparin.
7/31/2019 Thrombo Prophylaxis
6/120
5. In a patient with HITT
(which includes thrombosis),
why should you reverse any
existing warfarin therapy?
7/31/2019 Thrombo Prophylaxis
7/120
6. Which of the following is not adirect thrombin inhibitor?
a. Fondaparinux b. Lepirudin
c. Argatroban d. Bivalirudin
e. Danaparoid
7/31/2019 Thrombo Prophylaxis
8/120
INTRODUCTION
Venous thromboembolism (VTE),comprising deep vein thrombosis (DVT) andpulmonary embolism
(PE), has an annual incidence in Europe of60 -70 per 1000, 000 inhabitants.
Half of these occur in hospitalised patients
or those in care homes, and 25% in peoplewith no recognised risk factors.
7/31/2019 Thrombo Prophylaxis
9/120
The risk in the post-operative populationis higher still, with the incidence ofsubclinical DVT after total kneearthroplasty or hip fracture surgerybetween 40-60% and an incidence of PEin the same group of 4-10%.
In the UK, patients with a PE whoreceive treatment, have 14- and 90-daymortality rates of approximately 10%and 20%, respectively.
7/31/2019 Thrombo Prophylaxis
10/120
The House of Commons Health Committeereported in 2005 that an estimated 25,000people in the UK die from preventable hospital-acquired VTE every year.
It is our duty to do what we can to reduce theincidence of VTE by both understanding themechanism of formation, and ensuring correctprophylaxis is received.
There have recently been a number of advancesin the prevention of VTE, and this two-part seriesaims to summarise these, as well as reviewingolder prophylactic strategies.
7/31/2019 Thrombo Prophylaxis
11/120
This first tutorial will discuss thepathophysiology of VTE, identification ofhigh risk populations, and the presentationof DVT and PE.
It will then briefly cover the treatment ofthese conditions.
In the second tutorial, the mechanical andpharmacological methods of prevention
will be discussed.
7/31/2019 Thrombo Prophylaxis
12/120
THROMBOGENESIS
Thrombogenesis is a normal mechanism bywhich the body maintains haemostasis isresponse to injury.
Venous thromboembolism, however, is theabnormal development and propagation of aclot which is not useful.
The thrombus can cause local problems relatingto mechanical obstruction or blood flow.
In this situation, fragments of the thrombus canbreak off and cause further harm by similar
means.
7/31/2019 Thrombo Prophylaxis
13/120
The formation of a thrombus and its subsequentembolisation was first described by RudolphVirchow in 1856.
He subsequently described the eponymouslynamed Virchows triad.
In an environment where one or more of the
following conditions are met, there is a risk ofthrombogenesis; venous stasis, damage ordysfunction of the endothelium anhypercoagulability.
7/31/2019 Thrombo Prophylaxis
14/120
7/31/2019 Thrombo Prophylaxis
15/120
Activation of the
coagulation cascade
Tissue factor is located in the smooth muscle andadventitial layers or vessel walls; collagen is locatedin the subendothelial matrix.
When the endothelium is disrupted, the revelation ofeither of these compounds can initiate thrombusformation via platelet activation.
Coagulation can also be activated inappropriately,not just by trauma to the endothelium, but by
disruption, such as that caused by atheroscleroticplaques, turbulent blood flow or accumulation ofactivated clotting factors which may precipitatethrombus formation. immunological damage.Stagnant blood allows
7/31/2019 Thrombo Prophylaxis
16/120
Platelets Platelets are formed from the fragmentation
of a precursor called a megakaryocyte andhave a life span
of only 5 -9 days. The main function of aplatelet is to maintain haemostasis. Plateletsare responsible
for synthesis of Thromboxane A2 and withinthe cell there are granules containing many of
the mediators of coagulation; calcium, ADP, von
Willebrand Factor, fibrinogen, factors V andXIII.
7/31/2019 Thrombo Prophylaxis
17/120
The initial tethering of platelets to thesite of injury is mediated by glycoproteinIb receptors and Von Willebrand Factor
(vWF).
As the platelet plug forms there is aconformational change cause by actin
and myosin filaments within the cell. Contraction of the plug acts to reduce
the size of the vessel defect and stabilise
the plug.
7/31/2019 Thrombo Prophylaxis
18/120
Von Willebrand Factor Von Willebrand Factor (vWF) is found in
plasma, the endothelium and
megakaryocytes.
The binding of vWF to collagen or plateletglycoprotein complexes, facilitates the
formation of a thrombus. Absence of vWF factor causes a defect in
primary haemostasis and coagulation as
seen in von Willebrand Factor deficiency.
7/31/2019 Thrombo Prophylaxis
19/120
Formation of the thrombus
After initial adhesion of platelets to the site ofinjury, amplification of the coagulation
process must occur for a stable plug to form. The platelet integrin, glycoprotein IIb/IIIa, is
the main receptor for adhesion and
aggregation but other autocrine andparacrine mediators, including thrombin,thromboxane A2, epinephrine and adenosinediphosphate aid the haemostatic process.
7/31/2019 Thrombo Prophylaxis
20/120
The formation of thrombin
Thrombin is a potent initiator and
amplifier of the coagulation
cascade. When tissue factor is exposed, three
substrates, factor VII, factor IX and
factor X interact to form factor Xawhich converts prothrombin to
thrombin.
7/31/2019 Thrombo Prophylaxis
21/120
Thrombin then activates the flowingfactors; V, VIII, XI, as well as initiating theconversion of fibrinogen to fibrin.
Factor Va amplifies the conversion ofprothrombin to thrombin.
In its absence, the generation of thrombin
is 1% the rate of generation when factor Vais present.
7/31/2019 Thrombo Prophylaxis
22/120
Fibrinogen Fibrinogen, a soluble plasma
glycoprotein, is converted to fibrin
by the action of thrombin and plays
a great role in providing stability tothe platelet plug by bridging
glycoprotein IIb/IIIa integrins.
7/31/2019 Thrombo Prophylaxis
23/120
Modulators Calcium is an important co-factor in the
coagulation cascade without which haemostasis
would falter. It is only in the presence of both calcium and
factor Va that factor Xa can convert prothrombinto
thrombin on the cell membrane. Vitamin K is a fat soluble vitamin that is involved
in the carboxylation of glutamate residues onfactors
II, VII, IX, X and proteins C and S.
7/31/2019 Thrombo Prophylaxis
24/120
Negative feedback and
inhibition
Haemostasis is an incredibly careful balance
between pro- and anti-coagulant factors that
are omnipotent within the plasma and
endothelium.
As soon as the coagulation cascade is initiated,
the inhibitory mechanism is also activated.
When bound to thrombomodulin (found in theendothelium), thrombin activates protein C,
an inhibitor of the coagulation cascade and inthis way provides negative feedback, halting
the haemostatic process.
7/31/2019 Thrombo Prophylaxis
25/120
The action of Protein C
(inactivation of factors Va and
VIIIa) is slightly increased in thepresence of Protein S.
Antithrombin III, circulating inplasma, is also a potent
inactivator of thrombin.
7/31/2019 Thrombo Prophylaxis
26/120
Plasmin, derived from the
cleavage of plasminogen by tissue
plasminogen activator (t-PA) inthe endothelium, is responsible
for fragmenting fibrin and
destabilising the thrombus.
7/31/2019 Thrombo Prophylaxis
27/120
ASSESSMENT OF RISK
The National Institute of ClinicalExcellence (NICE) recently passed
guidance relating to VTE.
All patients admitted to hospital inthe United Kingdom should have
their risk of VTE assessed onadmission, allowing adequate
thromboprophylaxis to be instituted
immediately.
7/31/2019 Thrombo Prophylaxis
28/120
DIAGNOSIS OF VTE VTE has a variety of clinical
presentations and is often
asymptomatic. Symptomatic venous thrombosis
carries a considerable risk of long
term morbidity, due to venousulceration and development of post-
thrombotic limb secondary to
venous insufficiency.
7/31/2019 Thrombo Prophylaxis
29/120
Signs and symptoms of
DVT and PE Signs and symptoms of a DVT or PE may bevery subtle and unless actively searchedfor, can easily be missed.
Symptoms of a DVT include painful, red,swollen limb.
On examination the limb may be tender on
palpation, hardened or distended veinsmay be identified and there may be
discolouration or cyanosis.
7/31/2019 Thrombo Prophylaxis
30/120
The clinical presentation of a pulmonaryembolus may be even more vague.
Symptoms and signs include dyspnoea,
tachypnoea, chest pain, cough,haemoptysis, tachycardia, raised jugularvenous pressure, cyanosis, fever andcirculatory collapse.
There are a number of scoring systems tohelp guide investigation of a suspected PE,the one reproduced in the box below is thatwhich is recommended by the British
Thoracic Society (BTS)1:
7/31/2019 Thrombo Prophylaxis
31/120
The patient must have clinical features compatiblewith PE breathlessness and/or tachypnoea with orwithout pleuritic chest pain and/or haemoptysis
plus two other factors: (a) the absence of another reasonable clinical
explanation
(b) the presence of a major risk factor.
Where (a) and (b) are both true the probability ishigh; if only one is true
the probability is intermediate; and if neither is truethe probability is low.
7/31/2019 Thrombo Prophylaxis
32/120
Investigations
Leg Ultrasound
For suspected DVT, duplex ultrasonography of
femoral and popliteal veins has a sensitivity and specificity of around 97% in a symptomatic patient5.
Unfortunately there is limited accuracy in
compression ultrasound in detecting asymptomatic
proximal DVT and a single normal leg ultrasound, should not therefore, be used to exclude a subclinical
thrombus1.
7/31/2019 Thrombo Prophylaxis
33/120
D-dimer
D-dimer is a degradation product of cross-linkedfibrin. Raised D-dimer levels do not infer VTE as they
are present in many conditions such as pregnancy,peripheral vascular disease, cancer, inflammatoryconditions and hosptalised patients.
Newer second generation rapid D-dimer tests showsensitivities of 87-98% and combined with a lowclinical probability (using a scoring system such asthe one discussed earlier), a negative D-dimer canhave a negative predictive value of 97%.
7/31/2019 Thrombo Prophylaxis
34/120
If all patients with high, intermediate and lowclinical probabilities are included, then thenegative predictive value drops to 85% (usingthe SimpliRED assay)1.
The BTS recommend that the D-dimer is onlyused in cases where clinic suspicion of a PE or
DVT is low.
7/31/2019 Thrombo Prophylaxis
35/120
Isotope Lung Scanning
Isotope tests are reported as having high,
intermediate and low probability ofpulmonary embolism.
A normal or low probability isotope orventilation/perfusion scan, reliably excludes a
PE.
A high probability lung scan is not, however,diagnostic of one1.
7/31/2019 Thrombo Prophylaxis
36/120
The BTS recommends that an isotope scanshould only be the initial imaging investigation ifthere is: a normal, contemporaneous chest x-ray,no significant, symptomatic cardiopulmonarydisease, facilities are available on site,standardized reporting criteria are used and anon-diagnositc test is followed by furtherimaging.
This technique is useful in those patients whowould benefit from the lower radiation exposureas compared to the CTPA, such as obstetricpatients.
7/31/2019 Thrombo Prophylaxis
37/120
Computed tomography pulmonary angiogram(CTPA)
The availability of fast multi-slice scanners
has increased in the northern hemisphere andit is now the recommended first line imagingtechnique for PE.
Its superiority to the isotope scan is not onlythat it has a greater sensitivity and specificityfor PE but that, in the advent of a negativescan, it often reveals the true diagnosis.
7/31/2019 Thrombo Prophylaxis
38/120
The CTPA identifies a greater number ofemboli, but without improving outcome,when compared to the ventilation/perfusionscan.
A proximal clot can be reliably identified inaround 95% of studies and if the CTPA is
negative further treatment is not required.
7/31/2019 Thrombo Prophylaxis
39/120
Echocardiography ECHO can be diagnostic in
massive PE and may give
prognostic information,
however, it is less useful in mostother cases.
7/31/2019 Thrombo Prophylaxis
40/120
Other Investigations
Contrast venography is the gold standarfor PE diagnosisbut there is inter-observer
disagreement in up to a third of subsegmental thrombi. It is
still, however, more sensitive tosubsegmental thrombi than a CTPAd for DVT diagnosis in
all veins but is rarely carried out.
Alternate investigations include measurement of thethrombus burden, using radionuclide venography
and impedance plethysmography. Both are sensitive indetecting proximal but not distal thrombosis.
\
Pulmonary angiography is seen as the gold standard.
7/31/2019 Thrombo Prophylaxis
41/120
In patients with a PE the electrocardiogramoften demonstrates only a tachycardia.Infrequently there
may be right axis deviation, large S deflectionin lead I, a Q wave in lead III and inverted Twave in
lead III. T wave inversion in inferior andanterioseptal leads may also be indicative ofPE.
7/31/2019 Thrombo Prophylaxis
42/120
Chest X-ray is invariably unhelpful in thediagnosis of a PE although it candemonstrate Westermark sign (proximaldilation and distal constriction of the
pulmonary vasculature) and HamptonsHump (wedge shaped opacificationassociated with pulmonary infarction).
Although rare, if seen, these signs have highspecificities for PE.
Although it may not be of use in diagnosis ofPE, a chest x-ray may well elucidate an
alternative diagnosis.
7/31/2019 Thrombo Prophylaxis
43/120
TREATMENT OF VTE The initial treatment of any patient follows the
ABC approach .
Patients suspected VTE may need supportivetherapy and treatment based on clinical
judgement prior to definitive diagnosis.
Therapy may include: oxygen, fluid, inotropesand analgesia.
In the future there may be a place for pulmonaryvasodilators in treatment of a massive PE butcurrently, along with supportive management,the goals of treatment are to prevent furtherthrombus formation, and in some circumstances
precipitate breakdown of the thrombus.
7/31/2019 Thrombo Prophylaxis
44/120
These recommendations for treatment of anacute VTE are taken from the AmericanCollege of Chest Physicians2 (ACCP) who
issued guidelines in 2008.
The British Thoracic Society guidelines datefrom 2003 and differ only slightly.
NICE are in the process of developingguidelines for the treatment of VTE.
7/31/2019 Thrombo Prophylaxis
45/120
Anticoagulation
The ACCP guidelines state that anticoagulationwith unfractionated heparin (UFH), lowmolecular heparin (LMWH) and factor Xainhibitors is better than no anticoagulation for anacute PE or DVT.
The treatment of choice, however, is LMWHwithout regular factor Xa assays.
Direct thrombin inhibitors are also useful as theinitial treatment of VTE, although these are notmentioned in the guidelines
7/31/2019 Thrombo Prophylaxis
46/120
. If LMWH is unavailable and there is noability to monitor anti-Xa activity thensubcutaneous, fixed dose UFH can be used
(initial dose 333U/Kg followed twice daily250U/Kg).
A vitamin K antagonist (VKA) should be
started on day one and dual therapycontinued until the international normalised
ratio (INR) is > 2 for more than 24 hours.
7/31/2019 Thrombo Prophylaxis
47/120
In the case of massive PE then an IV bolus ofUFH may be given immediately as it is morerapid in onset than the LMWH.
Where the clinical suspicion of VTE is high,then treatment should be started beforedefinitive diagnosis.
In renal failure there is some evidence tosuggest that UFH is safer than LMWH.
7/31/2019 Thrombo Prophylaxis
48/120
Thrombolysis
For the majority of patients with VTE, thrombolysisis not recommended, however, the cliniciansdecision must be based on severity of the condition,
prognosis and risk of bleeding. There is a small population of patients that may
benefit from thrombolysis, namely any patient withhaemodynamic compromise including cardiacarrest, unless contraindicated due to bleeding risk.
If administering thrombolysis then a peripheral veinis preferred to a central catheter.
50mg Altepalase (a plasminogen activator) isrecommended by the BTS in the emergent situation.
7/31/2019 Thrombo Prophylaxis
49/120
Caval filters and embolectomy
In highly compromised patients who cannotreceive thrombolytic therapy then catheter
extraction or embolectomy may beconsidered.
The routine placement of a vena caval filter isnot recommended but in a patient with a highrisk of bleeding, obviating the use ofanticoagulation, then an inferior vena cavalfilter may be used.
7/31/2019 Thrombo Prophylaxis
50/120
Long term treatment
VKA, most commonly warfarin, provide themainstay of long term prophylaxis againstfurther VTE.
Anticoagulation with VKA for at least 3 months,with a target INR 2.5, is recommended for allpatients (BTS advise 6 weeks in those with norisk factors).
Long term anticoagulation must be assessed inconjunction with the individual patients risk ofbleeding and on-going risk factors for VTE.
7/31/2019 Thrombo Prophylaxis
51/120
IMPORTANT POINTS/SUMMARY BOX
VTE is a major cause of mortality andmorbidity
Appropriate thromboprophylaxis should beconsidered for patient admitted into hospital
Appropriate diagnostic tests and imagingdepends on the findings of a targeted clinical
history and examination
7/31/2019 Thrombo Prophylaxis
52/120
ANSWERS TO QUESTIONS
1. F/T/F/T
2. Proteins C and S are anticoagulant co-factors
3. malignancy, varicose veins, post-operative
intensive care
7/31/2019 Thrombo Prophylaxis
53/120
Heparin induced
thrombocytopaenia (type II)is a life-threatening syndrome that may occur after
exposure to unfractionated or (in rare cases) low-molecular-weight heparin. HITis usually suspected
after an incidental finding of thrombocytopaenia following administration ofheparin, where there is no
clear alternative cause for the fall in platelet count. Detection of thethrombocytopaenia and accurate
diagnosis (or strong clinical suspicion), are key aspects in the management ofHIT. Once the diagnosis
has been committed to, treatment must be immediately initiated to combatsome of the potentially
catastrophic effects of the disorder. The principal goal of managing heparininduced
thrombocytopaenia is to reduce the risk of thrombosis by decreasing furtherplatelet activation and
thrombin generation.
7/31/2019 Thrombo Prophylaxis
54/120
There are seven key aspects of treating hit:
1. Discontinue heparin.
2. Continue to monitor platelet counts.
3. Avoid giving warfarin until platelet counts recover.4. Test for HIT antibodies (if not already tested for).
5. Evaluate for the presence of deep veinthrombosis.
6. Platelet transfusions are ONLY given to treatbleeding, NOT the thrombocytopaenia.
7. Anticoagulate with a non-heparin regimen.
7/31/2019 Thrombo Prophylaxis
55/120
DISCONTINUE ALL HEPARIN
In most cases, patients with HIT have recently been exposed to a heparin source: heparin flushes,intraoperative
anticoagulation, subcutateous injection for thrombophrophylaxis, or haemodialysis.
Whatever the situation, once your suspicion of HIT has been adequately confirmed; ensure allsources
of heparin are discontinued, and notify all caregivers. Interestingly, a retrospective analysis2
demonstrated that timely discontinuation of heparin was no more effective in reducing morbidityand
mortality than late heparin cessation. This demonstrates that, while ceasing heparin is a vital partof
management, multimodal therapy is important in ultimately decreasing the morbidity andmortality.
The thrombocytopaenia associated with HIT may continue to worsen, even after discontinuingheparin
administration. Recovery of the platelet count is a good sign that HIT has regressed and isresponding
to therapeutic measures.
7/31/2019 Thrombo Prophylaxis
56/120
HIT is usually suspected and investigated afteran incidental platelet count reveals
thrombocytopaenia.
Until the nadir of the patients platelet count hasbeen established, and there is a clear rise in the
platelet count, the patients platelet levelsshould be evaluated daily (when resources
allow). In severe
cases of thrombocytopaenia, haemoglobin levelsshould also be monitored for signs of subclinical
bleeding.
7/31/2019 Thrombo Prophylaxis
57/120
WARFARIN AND LOW MOLECULARWEIGHT HEPARIN (LMWH)
LOW MOLECULAR WEIGHT HEPARIN
Low molecular weight heparin is not anappropriate alternative for anticoagulation in
HIT. There is an
in-vivo cross-reactivity between UFH andLWMH in approximately 50% of cases.
7/31/2019 Thrombo Prophylaxis
58/120
WARFARIN
Warfarin monotherapy in active heparin inducedthrombocytopaenia is contraindicated, based on
multiple reports of warfarin induced skin necrosis and
venous gangrene in the limbs. Affected patientstypically have a supratherapeutic INR (typically above 4.0).
The risk of thrombosis in HIT patients
started on warfarin is 38-76% within the first month despitecomplete discontinuation of heparin. For
this reason it is recommended that warfarin not be starteduntil adequate resolution of the patients
thrombocytopaenia has occurred (preferably, plateletcounts above 150,000 ! 109/L).
7/31/2019 Thrombo Prophylaxis
59/120
In some cases, HIT is diagnosed after warfarintherapy has already been initiated. In this situation,
it is
recommended to reverse warfarin anticoagulationwith vitamin K. This reversal reduces the risk of
warfarin necrosis, and minimizes the risk of directthrombin inhibitor (DTI) underdosing, as warfarin
prolongs the activated partial thromboplastin time(aPTT), which is used to monitor DTI levels, as well
as the PT.
7/31/2019 Thrombo Prophylaxis
60/120
REVERSAL OF HEPARIN
The reversal of vitamin K antagonists (warfarin), should be conducted byadministering vitamin K 5-10
mg orally or iv. Evaluation of the International Normalised Ratio (INR) and aPTTshould be done
roughly 6 hours later to evaluate the effectiveness of the vitamin K dosing. Thedoes can be repeated,
if necessary.
HIT ANTIBODIES
In a patient with clinically suspected HIT (where the pre-test probability is high),more definitive
confirmation by testing for the presence of HIT antibodies helps to guidetreatment and prevents
missing an alternative diagnosis. Specifics on the types of testing available aredetailed inpart 1 of this
tutorial.
7/31/2019 Thrombo Prophylaxis
61/120
DEEP-VEIN THROMBOSES
Anticoagulation is required for at least 2 to 3 monthsafter the resolution of HIT (see below) to prevent
and treat thrombosis. Thrombosis in HIT is one ofthe more serious complications, and as a result
requires vigilance in monitoring and prompttreatment if detected. In patients with HIT who
develop
thrombosis, there is an associated mortality ofapproximately 2030%, and an equal percentage will
become permanently disabled by amputation,stroke or other causes.
7/31/2019 Thrombo Prophylaxis
62/120
Thromboembolic complications can bevenous, arterial (or both) and include:
1. Deep venous thrombosis (DVT)
2. Pulmonary embolism (PE)
3. Myocardial infarction (MI)
4. Thrombosis and ischemia of limbs via
arterial occlusion.
7/31/2019 Thrombo Prophylaxis
63/120
The type and site of thrombosis varies depending on the patientand some of their inherent risk factors.
DVTs and PEs are most common in postoperative patients. Whilethe incidence of deep vein
thrombosis in orthopaedic patients who received heparin forthromboprophylaxis was 17.8%, those
with HIT have a DVT incidence that approaches 89%. Even afterdiscontinuation of heparin, patients
with HIT have a 38-76% risk of developing thromboticcomplications in the first month.
Therefore, an essential component to treatment of the patientwith HIT is vigilance in monitoring for
the development or existence of thrombi, and optimizingtreatment to prevent further occurrence.
PLATELET
7/31/2019 Thrombo Prophylaxis
64/120
PLATELET TRANSFUSIONS
Even though patients with HIT can be severelythrombocytopaenic, the transfusion of platelets in an
attempt to avoid bleeding is generally unnecessary. Even
when severe throbocytopenia occurs in HIT,petechiae and other mucocutaneous bleeding that would
typically be found in patients with non-HIT
thrombocytopaenia are rare. Paradoxically, platelettransfusions have been linked with thrombotic
events in some reports. When the diagnosis of HIT is uncertainand there is a high bleeding risk (as
judged by the clinician), or if significant bleeding occurs,platelet transfusions may be appropriate.
7/31/2019 Thrombo Prophylaxis
65/120
ALTERNATIVE ANTICOAGULATION
As mentioned above, the thrombotic aspect of HIT is aserious comorbidity that should be prevented,
monitored, and treated if discovered. The pathophysiology
of HIT involves extensive plateletactivation, and thrombocytopaenia secondary to platelet
clumping/consumption. Hence, once the
diagnosis of HIT is committed to, and heparin isdiscontinued, alternative thromboprophylaxis should
be initiated.Until it is safe to restart heparin or warfarin, a range of
newer and developing anticoagulants may be
utilized for thromboprophylaxis.
7/31/2019 Thrombo Prophylaxis
66/120
INITIATION OF ALTERNATIVE ANTICOAGULATION
Non heparin alternate anticoagulants should be given for at least 14 days totreat and prevent
thrombosis. Preferred alternatives are lepirudin or argatroban.
1. Special monitoring tests are required for these medications.
2. Doses should be reduced in cases of renal and hepatic insufficiency.
3. Once the platelet count rises above 150,000 ! 109/L, oral warfarin may beinitiated with careful
overlapping with a nonheparin anticoagulant for at least 5 days.
4. If a life saving procedure like coronary artery bypass graft (CABG),percutaneous coronary
intervention (PCI) or haemodialysis is required during acute HIT, the alternative,nonheparin
anticoagulant of choice will depend upon the resources at your facility(availability of medication
and ability to monitor levels of anticoagulation).
7/31/2019 Thrombo Prophylaxis
67/120
7/31/2019 Thrombo Prophylaxis
68/120
DIRECT THROMBIN INHIBITORS
Direct thrombin inhibitors work in the final commonpathway of the clotting cascade (see figure 1).
They directly bind and inactivate thrombin (alsoknown as factor IIa). This prevents the conversion of
fibrinogen to fibrin (a key component to theproduction of a hemostatic plug or clot).
Direct thrombin inhibitors have short half-lives,show no cross-reactivity to heparin, and unlike
heparin, do not require antithrombin to function.
7/31/2019 Thrombo Prophylaxis
69/120
Lepirudin
Lepirudin is recombinant hirudin (originally produced by leeches),which directly inhibits thrombin by
irreversibly binding to it. In patients with HIT, studies havedemonstrated that anticoagulation with
lepirudin significantly lowered mortality, new thromboembolism,and limb amputation.
Of note, lepirudin is renally cleared, and caution should be takenin those with renal dysfunction.
Antibodies to lepirudin develop in 30% of patients after initial
exposure and in 70% of patients afterrepeated exposure. Because fatal anaphylaxis has been
reported upon repeat administration of
lepirudin,patients should not be treated with this agent morethan once.
7/31/2019 Thrombo Prophylaxis
70/120
Argatroban
This is an arginine-based synthetic anticoagulant, which directly inhibitsthrombin and reversibly binds
the catalytic site of thrombin. Of note, Argatroban is hepatically cleared, andcaution should be taken in
patients with liver dysfunction. In these patients, it is recommended to reducethe dose by 75%.
Bivalirudin
Bivalirudin is another synthetic thrombin inhibitor that has been approved forpercutaneous coronary
intervention in patients who have, or are at risk for, heparin-inducedthrombocytopaenia (table 2).
Because of its short half-life, bivalirudin shows promise as a potentialanticoagulant in cardiac bypass
surgery, but its use in treating heparin-induced thrombocytopaenia has not beenstudied in clinical
trials.
7/31/2019 Thrombo Prophylaxis
71/120
7/31/2019 Thrombo Prophylaxis
72/120
FACTOR Xa INHIBITORS
Danaparoid
Danaparoid is a mixture of three glycosaminoglycans(heparin sulphate, dermatan sulphate and
chondroitin sulphate) which, via antithrombin, inhibits anti-factor Xa activity. Recent studies in HIT
associated thrombosis showed a 90% treatment successrate with danaparoid. Danaparoid has a long
anti-factor Xa half-life of roughly 25 hours. Danaparoid can
be given intravenously (see table) orsubcutaneously if the intravenous route is not practicable.
In this case it can be given as 1250U
subcutaneously followed by 2000U twice a day.
7/31/2019 Thrombo Prophylaxis
73/120
The dose should be adjusted to maintainplasma anti-Xa levels within 0.50.8 U/mL
(this requires
facilities that have the ability to rapidly testfactor Xa levels). If surgery or other invasive
procedures
are planned, danaparoid should be stoppeduntil the anti-Xa level is less than 0.4.
7/31/2019 Thrombo Prophylaxis
74/120
Fondaparinux
Fondaparinux is a synthetic heparin pentasaccharide thatdoes not cross-react with HIT antibodies, and
is a favourable candidate for anticoagulation in patients
with HIT. It has a long half-life of roughly 17hours, and is recommended as prophylaxis for post-
operative thrombosis by daily subcutaneous
injection of 2.5mg. Despite its theoretical potential, thereare few publications supporting the use of
fondaparinux in HIT and other thrombocytopenicsituations. Further studies are required before a
definitive recommendation can be made on its use in HIT.
7/31/2019 Thrombo Prophylaxis
75/120
7/31/2019 Thrombo Prophylaxis
76/120
ALTERNATIVE ANTICOAGULATION IN LATER STAGES OF HIT
Subacute HIT
At this stage, platelets have generally recovered and are stable at levelsof 150,000!109/L or above, but
the patient is still HIT antibody positive.
1. Avoid reintroduction of heparin for at least 100 days to minimize theincreased risk of thrombosis.
2. Alternative anticoagulation may be utilized in emergency situations(CABG, PCI, dialysis)
Previous HIT, but normal platelet count, and no detectable HIT antibodies
1. Short-term exposure to heparin may be safe, but should be utilizedonly in emergency situations.
2. Alternative anticoagulants may be used if there is a concern of HITrecurrence.
3. Bivalirudin may be considered as drug of choice for PCI.
7/31/2019 Thrombo Prophylaxis
77/120
SUMMARY
If HIT is confirmed or seriously suspected:stop all heparin.
Follow platelet trends
Evaluate and monitor for arterial and/orvenous thrombosis
Commence alternative anticoagulation
7/31/2019 Thrombo Prophylaxis
78/120
ANSWERS TO QUESTIONS
1a: FALSE. Platelet transfusion should bereserved for patients with documentedbleeding, as further platelet loads areassociated with thrombosis in HIT.
1b: TRUE. Because of the incidence and
morbidity/mortality of HIT associatedthrombosis, prophylaxis should be initiatedafter discontinuation of heparin.
7/31/2019 Thrombo Prophylaxis
79/120
1c: FALSE. Because of the sensitivity of theHIT antibody test, it serves as an excellent testto rule out HIT.
Likewise, the availability of a HIT antibody testis not essential for diagnosing HIT.
A diagnosis of HIT can be made on clinicalgrounds if an antibody test is not available.
1d: FALSE. HIT is not an allergic condition.
While HIT is an antibody mediated condition,it does not involve systemic histamine release oranaphylactic/anaphylactoid characteristics.
.
7/31/2019 Thrombo Prophylaxis
80/120
2: When utilizing warfarin in HIT patients, asevere reduction in protein C can develop,resulting in a failure to control thrombingeneration.
As a result, thrombosis in HIT patients startedon warfarin can reach 38-76% within the firstmonth, despite complete discontinuation of
heparin. 3: a and e. Fondaparinux and danaparoid are
NOT direct thrombin inhibitors but anti-factorXa agents
7/31/2019 Thrombo Prophylaxis
81/120
Anticoagulation is a very common form of medical intervention
which is increasingly used for primary or secondary prevention
of thromboembolic complications of vascular disease. Oralanticoagulation
with vitamin K antagonists (VKAs), mainly warfarin,is almost the unique tool for chronic anticoagulant treatment
in clinical practice, although newer anticoagulants have already
been approved or evaluated in clinical studies. Anticoagulation
with VKAs has been shown to be effective in the prevention and
treatment of thrombotic complications in various clinicalsettings,
including atrial fibrillation, venous thromboembolism
(VTE), acute coronary syndromes and after invasive cardiacprocedures.
7/31/2019 Thrombo Prophylaxis
82/120
In spite of the sharp increase in the number of anticoagulated
subjects which has occurred in recent years (an increase
of 45% of warfarin prescriptions between 1998 and 2004
has been recorded in the USA [1]), numerous studies have documented
an under-use of anticoagulation in subjects, especially
elderly, who would benefit from this therapy (2, 3). Adequate
treatment with VKAs is rather demanding, for both the patients
and the health care systems, because periodic laboratory monitoring
is necessary to maintain the effect of the drug in a therapeutic
range and to minimize adverse events (46). Bleeding is
the most important complication of VKAs and a major concern
for both physicians and patients.
7/31/2019 Thrombo Prophylaxis
83/120
The incidence of bleeding varies widely inpublished studies. In
part, the difference in reported rates can be
attributed to the diverse
classification of bleeding events (major, life-threatening
and minor) adopted in single studies.
7/31/2019 Thrombo Prophylaxis
84/120
randomised clinical trials record lower rates ofbleeding than observational
studies because they usually include only highly
selected patients.Very elderly patients are almost always
excluded in these studies
Up to one third of patients evaluated for
participation in clinical trials on VKAs use in atrialfibrillation were judged for a high perceived
bleeding risk (7, 8).
7/31/2019 Thrombo Prophylaxis
85/120
It is, in fact, well known that the first few months of
treatment are associated with a higher rate of complications (9,
10.)
Such studies may therefore underestimate the rate of bleeding
by missing early complications and early cessation of VKA
in patients at a high risk of bleeding. In a recent analysis of clinical
studies characterised by careful monitoring of anticoagulant
intensity, it has been calculated that VKA treatment increases the
risk of major bleeding by 0.3 0.5% per year. In these studies the
risk of intracranial hemorrhage (ICH), which is the major if not
the exclusive cause of death and disability associated with VKA
treatment (11), is increased by approximately 0.2% per year
when compared to controls (12).
7/31/2019 Thrombo Prophylaxis
86/120
The absolute risk of major bleeding complications in specialised
anticoagulation services ranged from 0.32% to 2.1% per
year, and of fatal bleeding from 0% to 0.25% per year (13). Asignificant
clinical impact of bleeding in patients anticoagulated for
VTE has been demonstrated in a recent meta-analysis ofavailable
clinical trials that reported a case-fatality rate of major
bleeding of 13.4% in all patients (95% confidence interval [CI],
9.4% to 17.4%), with a rate of ICH of 1.15% patient-years (95%CI, 2.5% to 21.7%) (14).
7/31/2019 Thrombo Prophylaxis
87/120
Major bleeding with VKA treatment can be not onlylifethreatening,
such as ICH, but also associated with significant
morbidity, while even minor bleedings may be important for the
related inconvenience to the patients. Altogether, the risk of
bleeding associated with VKAs limits their more widespread use
and denies many patients the benefits of a useful therapy. It has
been shown (15) that the occurrence of VKA-associated adverse
events has an impact on the prescription of this treatment, since
physicians are less likely to prescribe VKAs after observing
major bleeding during VKA treatment in their patients.
7/31/2019 Thrombo Prophylaxis
88/120
Intensity of anticoagulation
The intensity and duration of anticoagulation are main factors
associated with the risk of bleeding. A strong relationship between
the intensity of anticoagulation and the risk of bleeding
has been demonstrated by several experimental trials (in various
clinical conditions) in which patients were randomised to different
anticoagulation levels (12). Though bleeding is not always related
to a high intensity of anticoagulation and may occur even in
association with very low international normalised ratio (INR)
values (< 2.0), the intended intensity of anticoagulation and especially
the actually achieved intensity are major determinants
of anticoagulation-induced bleeding.
7/31/2019 Thrombo Prophylaxis
89/120
The increase in bleeding
incidence becomes exponential for INR values > 4.5,while the
lowest rate is associated with INR results between
2.0 to 3.0 INR(9). The risk of death is also strongly related to the
INR level,
with a minimum risk at 2.2 INR. High INR values are
associatedwith an excess mortality as well: for one unit INR
increase above
2.5 there is a two-fold risk increase (19).
7/31/2019 Thrombo Prophylaxis
90/120
Timing from starting of anticoagulation
The first period of anticoagulation and inparticular the first 90
days are associated with a higher rate ofhaemorrhages (9, 10).
This can be attributed to different factors: occultlesions can be
unmasked at the beginning of anticoagulanttherapy, and/or the
dose adjustment may be less adequate in thatperiod.
7/31/2019 Thrombo Prophylaxis
91/120
Quality of monitoring
A poor control of anticoagulation is undoubtedly an important
factor leading to an increased risk of complications. A way to
evaluate the quality of anticoagulation control is to calculate the
time spent within the therapeutic range (time-in-range). A strongrelationship between time-in-range and bleeding or
thromboembolic
rates has been observed in many studies, involving different
patient populations and different target ranges (20).
7/31/2019 Thrombo Prophylaxis
92/120
Higher
rates of annual mortality and major bleedingevents have been
recorded in a poor control group of patients(4.20% and 3.85%,
respectively) compared to a good control
group (1.69% and
1.58( )%21.)
7/31/2019 Thrombo Prophylaxis
93/120
Many factors may affect the quality of anticoagulation
monitoring. A better overall quality of treatment and a
more stable anticoagulation has been reported by using coumarin
drugs with long-lasting action, such as warfarin (22) or phenprocoumon
(23), versus the short half-life drug acenocoumarol.
Patient information and education and the systems adopted for
INR control are also factors affecting the quality of treatment. A
better quality control in patients who had received a satisfactory
education has been reported (24), as well as an improvement in
their time-in-range in highly unstable patients after a supplementary
education course (25).
For personal
7/31/2019 Thrombo Prophylaxis
94/120
7/31/2019 Thrombo Prophylaxis
95/120
Person-dependent factors
Genetic factors
Though for decades VKAs have been the most usedantithrombotic
drugs, only recently our understanding of their mechanismsof action and of the broad inter-individual variability in
the sensitivity to these drugs has greatly improved thanksto the
knowledge on their pharmacogenetics (for a complete
review see[30.)]
7/31/2019 Thrombo Prophylaxis
96/120
At least 30 genes have been associated with themetabolism
and action of warfarin. Some polymorphisms of genes thatencode
for the vitamin K epoxide reductase enzyme (VKORC1)and for the cytochrome P-4502C9 enzyme (CYP2C9) are
responsible
for the large inter-individual variations in doserequirements,
and can predispose to overdosage conditions and a higherrisk of bleeding (31, 32).
7/31/2019 Thrombo Prophylaxis
97/120
Age
Throughout most (9, 4649), though not all (50, 51),studies age
is generally regarded as a risk factor for bleeding
during VKAtreatment. A recent review of the studies (52)
reported rates of
3.2% and 0.64% patient-years, for major and fatal
bleeding respectivelyin subjects aged 69 years or older compared to 0.6%
and 0.12% patient-years in subjects aged 40 years orless.
7/31/2019 Thrombo Prophylaxis
98/120
The
risk of ICH, the most important and feared type of haemorrhage
during VKA, is particularly increased in advanced age (47). Its
incidence is estimated to be 0.2% to 1.0% patient-years in all
anticoagulated patients (53), but increases to 1.1% patient-yearsin patients above 75 years (54). A recent study (55) reported an
adjusted odds ratio of 2.5 (95% CI, 134.7) of ICH in patients
aged 85 or more versus a reference group of patients of 7074
years. In line with previous reports (54), this study showed that
values of INR less than 2.0 were not associated with lower risk ofICH compared with values between 2.0 and 3.0.
7/31/2019 Thrombo Prophylaxis
99/120
Elderly subjects are exposed to higher risk for bleedingcomplications
during VKA for several reasons. They require lower
anticoagulant doses than younger subjects, mainly because ofreduced
metabolic clearance (56) especially in older women. It hasbeen recently shown that, when warfarin is being initiated, the
commonly used starting daily dose of 5 mg per day may lead to
overanticoagulation for the majority of elderly patients and a
lower initiation and maintenance dose has been recommendedfor these patients (57).
7/31/2019 Thrombo Prophylaxis
100/120
Elderly patients have a higher prevalence
of co-morbid conditions (58) and are more likely to be takinginteracting
drugs. They more frequently have pathological changes
in cerebral vessels, such as leukoaraiosis and amyloid angiopathy,
that may increase the risk of ICH (59, 60). They are at
higher risk for falls with a subsequent substantially increased
risk of intracranial haemorrhage (61). The incidence ofgastrointestinal
haemorrhage increases sharply with age (62), due to themorefrequent presence of diverticulosis, malignancy, angiodysplasias,
and ischaemic colitis, all more common in the elderly
population.
7/31/2019 Thrombo Prophylaxis
101/120
Although reported to be similar in elderly and
younger patients (63), non-compliance to VKAs maycontribute
to the complexity of the drug regimen and a higher
instability ofanticoagulation levels. A lack of a clear
understanding of the purpose
and mechanisms of this treatment by the elderly (25)
whoare also prone to mental impairment (64) may also
contribute to
a low compliance with the treatment.
7/31/2019 Thrombo Prophylaxis
102/120
It can be concluded that elderly patients shouldnot be excluded
from anticoagulation therapy only because oftheir age if
they are otherwise good candidate to thetreatment. These subjects
should, however, be monitored carefully andfrequently to
maximise their stability during anticoagulationand to reduce the
risk of complications.
7/31/2019 Thrombo Prophylaxis
103/120
Gender
A greater risk of bleeding (66) or of borderline significance(67)
was reported in women than in men treated for atrialfibrillation,
although no significant difference in bleeding rate between
males and females was found in observational studiesenrolling
patients with various indications for VKA (9). Pengo et al.
(68)found a higher frequency of major bleeding in females
treated for
atrial fibrillation at univariate analysis.
7/31/2019 Thrombo Prophylaxis
104/120
Non-compliant patients
were found to be more frequently young, male and not havingalready
experienced a thromboembolic event (63). Unstable patients,
more frequently than stable ones, reported they were
poorly informed on the reasons and the clinical importance of
anticoagulation for their health; many of them also hadinsufficient
knowledge of VKA mechanism of action, the rules of treatment-
monitoring, and the risk of thrombotic and bleedingcomplications
(25.)
7/31/2019 Thrombo Prophylaxis
105/120
A relationship between patient knowledge of
anticoagulation mechanisms and quality of control has beenreported
(69, 70). Moreover, patient education on VKAs andanticoagulation
training has been effective in reducing the risk ofmajor bleeding in older patients (71). These data indicate that
patient
knowledge of VKAs treatment and its management is a primary
determinant of the quality of anticoagulation control and
that appropriate education and information of patients is one of
the most important tasks of services dedicated toanticoagulation
monitoring.
7/31/2019 Thrombo Prophylaxis
106/120
Dietary modification has long been recognised as a key factor
for instability of anticoagulated patients. Patients who increase
their dietary vitamin K intake may become resistant to
VKA effect (72, 73). On the contrary, a lower intake of vitamin K
has been demonstrated to increase sensitivity to VKAs (74, 75).A reduction in dietary vitamin K intake should be expected in
sick patients who are treated with antibiotics and intravenous
fluids without vitamin K supplementation and in patients who
have states of fat malabsorption.
7/31/2019 Thrombo Prophylaxis
107/120
It is possible that at least part of
the instability of anticoagulation control in patientson VKA
therapy is attributable to a low dietary intake and/orlow reserves
of vitamin K. A low-dose vitamin K supplementation(100 to 200
mcg daily) proved to be effective in improving thequality of anticoagulation
control (76, 77), a result that has been confirmed by
two recent trials (78, 79).
7/31/2019 Thrombo Prophylaxis
108/120
Fever or other hypermetabolic states, such as hyperthyroidism,
may increase VKAs responsiveness, probably by increasing
the catabolism of vitamin K-dependent coagulation factors.
The use of nutritional supplements and/or herbal products is
particularly problematic in VKA-treated patients for the little orno standardisation of their content and for the possible effects
on
anticoagulation stability. Unfortunately, such products arefrequently
taken by patients monitored in anticoagulation clinics
(80) often without informing the doctors in charge.
7/31/2019 Thrombo Prophylaxis
109/120
Co-morbid conditions
The presence of co-morbidities may represent a significant risk
factor for bleeding during treatment. A recent analysis of results
of a clinical trial on treatment of patients with AF (the AFFIRM
Study [81]) reported that congestive heart failure, hepatic orrenal disease and diabetes were conditions, among others,
significantly
associated with major bleeding. A history of bleeding
(especially in the gastro-intestinal tract) is the patient relatedfactor
most frequently reported to be predictive for the risk of
further bleeding complications (82).
7/31/2019 Thrombo Prophylaxis
110/120
Liver diseases potentiate
the response to VKAs by impairing synthesis of coagulationfactors
and usually make a good control of anticoagulation more
difficult. In a recent review (83) of the available studies,several
possible predisposing factors have been analysed: historyof
bleeding, history of myocardial infarction and previous
cerebrovascularevents were all factors associated with higher risk
of bleeding complications.
7/31/2019 Thrombo Prophylaxis
111/120
Blood pressure control is a critical factor for bleedingcomplications
during VKA. A higher prevalence of history of hypertension
in anticoagulated patients with bleeding versus patients
without bleeding complications was found in some (84), though
not all studies (55). No relationship was found between quartiles
of systolic blood pressure and bleeding complications in the
SPORTIF cohorts (85). These result can reflect the optimalmanagement
and close monitoring typical of a clinical trial setting. It
has been reported that a modest blood pressure-lowering halves
the occurrence of ICH during antiplatelet therapy (and likely
during anticoagulation) (86).
7/31/2019 Thrombo Prophylaxis
112/120
The association between malignancy and VTE is wellestablished.
The ISCOAT study showed that a malignant disease was
significantly more common in patients who started oralanticoagulation
for VTE than in patients who were treated with
VKAs for other indications (11.3% vs. 2.9%, respectively; p